IRVINE, Calif., Nov. 10, 2015 /PRNewswire/ -- ALPHAEON Corporation and its subsidiary company PRN Physician Recommended Nutriceuticals, LLC (PRN), a leading provider of nutritional supplements, today announced that the U.S. Patent and Trademark Office issued to PRN U.S. Patent No. 9,115,078 "Compositions for Improving the Quality of the Meibum Composition of Inflamed or Dysfunctional Meibomian Glands."
The patent is another major milestone for PRN. A recent study positively assessed the effect of the company's oral re-esterified triglyceride omega-3 fatty acids for patients with occasional dry eye symptoms. Dry eye symptoms can include dryness, itching, burning, sensitivity to light and blurry vision. This new 3:1 patented composition delivers a total amount of 2668mg Omega-3 essential fatty acids1.
Dr. Michael Gross, Chief Medical Officer for PRN, stated, "We believe in putting clinical data and scientific evidence behind our products and this patent is testament to that commitment. I could not be prouder of the hard work and dedication that went into this effort."
Ken Krieg, PRN's Chief Executive Officer added, "The granting of our patent further establishes our leadership position in providing high quality nutriceuticals. Our supplements can offer real relief and benefits to consumers with occasional dry eye symptoms, and we're thrilled with the recognition."
To learn more about PRN visit: http://alphaeon.com/prn.
About ALPHAEON Corporation
ALPHAEON Corporation is a social commerce company with the goal of transforming self-pay healthcare by bringing to market highly innovative products and services to promote consumer wellness, beauty and performance. The company works in partnership with board certified physicians ensuring access to leading advancements in lifestyle healthcare. For more information, please visit www.alphaeon.com.
About PRN Physician Recommended Nutriceuticals
PRN is a leading developer of omega-3 products and nutritional supplements. Developed by doctors and recommended by world-renowned medical thought leaders, PRN's products are supported by medical evidence and offer exceptional quality and purity. PRN was recently acknowledged on the Inc. 5000 list of fastest growing privately held companies. PRN is a subsidiary of ALPHAEON Corporation.
1. Data on file, ALPHAEON corporation
SOURCE ALPHAEON Corporation